<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02225158</url>
  </required_header>
  <id_info>
    <org_study_id>140178</org_study_id>
    <secondary_id>14-I-0178</secondary_id>
    <nct_id>NCT02225158</nct_id>
  </id_info>
  <brief_title>Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection</brief_title>
  <official_title>Longitudinal Study of Immune Responses to Mycobacterium Tuberculosis (Mtb) in Subjects With Latent Tuberculosis (TB) Infection(LTBI) With or Without Concomitant Helminth Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Tuberculosis (TB) is a severe disease and a major cause of death in many people worldwide. It&#xD;
      is caused by a bacteria that enters through the lungs and can spread elsewhere in the body.&#xD;
      People with latent TB have the bacteria that lie dormant but can become active and cause&#xD;
      disease. These people are offered treatment to prevent development of active TB. Worldwide, a&#xD;
      lot of people with LTBI also have a parasitic worm called a helminth that can stay in the gut&#xD;
      or the blood. These parasites can affect the immune system and cause diseases like TB to&#xD;
      become worse. Researchers want to see how helminth infection makes it harder for people to&#xD;
      fight TB infection.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To study how the immune system of people with latent tuberculosis infection (LTBI) acts to&#xD;
      prevent development of active TB. Also, to study how helminth infection might affect this&#xD;
      immune response.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Adults age 18 70 with LTBI as defined by an approved blood test called QuantiFERON TB&#xD;
           Gold.&#xD;
&#xD;
        -  No evidence of infections like Hepatitis or HIV&#xD;
&#xD;
        -  Pregnant subjects and subjects taking medications that suppress the immune system are&#xD;
           not eligible.&#xD;
&#xD;
        -  Have not received prior treatment for LTBI. Participants might be still eligible if&#xD;
           prior treatment for active TB has been received&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Screening phase:&#xD;
&#xD;
      - Participants will be screened with medical history, physical exam, and blood tests for&#xD;
      other infections/conditions which might affect the immune system. They will have testing for&#xD;
      active TB i.e. blood testing as well as testing of their spit, scans and X-rays.&#xD;
&#xD;
      Baseline phase:&#xD;
&#xD;
        -  Only eligible participants will be entered into the study.&#xD;
&#xD;
        -  Participants will have interviews, medical history, and physical exam.&#xD;
&#xD;
        -  Blood will be drawn from an arm vein for testing.&#xD;
&#xD;
        -  Participants will collect stool samples at home for 3 days in a row to test for helminth&#xD;
           infection..&#xD;
&#xD;
        -  Participants may have apheresis. Blood cells are removed by needle. They pass through a&#xD;
           separator machine which returns everything but the cells back to the participant.&#xD;
&#xD;
        -  Participants may have procedures at the start and end of the study that let researchers&#xD;
           look into the lungs and collect cells.&#xD;
&#xD;
      Study phase, about 2 years:&#xD;
&#xD;
        -  All participants will be offered treatment for LTBI which lasts 6-9 months.&#xD;
&#xD;
        -  Participants being treated for LTBI will have about 11 study visits. They will visit&#xD;
           monthly for 9 months while on treatment, then 6 and 12 months after treatment.&#xD;
&#xD;
        -  Participants not eligible/refusing treatment for LTBI will be made aware of active TB,&#xD;
           then have 3 other visits, about 6, 12, and 24 months after the baseline visit.&#xD;
&#xD;
        -  Participants who have helminth infection will receive appropriate treatment.&#xD;
&#xD;
        -  All participants will have blood drawn at each visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mycobacterium tuberculosis (Mtb) infection remains an important cause of morbidity and&#xD;
      mortality worldwide. A problem for eradication efforts is the large reservoir of ~2 billion&#xD;
      people with latent tuberculosis (TB) infection (LTBI) and poor understanding of factors&#xD;
      leading to active disease progression. Helminth infections geographically overlap with Mtb&#xD;
      and induce significant immune-mediated modulation. Although CD4+T cells producing IFN-gamma&#xD;
      and TNF-alpha have been implicated in protective immunity to TB, a detailed description of&#xD;
      the evolution of protective and immunomodulatory responses in LTBI is lacking. Additionally,&#xD;
      there is incomplete understanding of how the immunomodulation caused by helminth co-infection&#xD;
      affects such responses.&#xD;
&#xD;
      This protocol will attempt to fill this knowledge gap through comprehensive longitudinal&#xD;
      immunological analyses of two populations of subjects with LTBI, with or without concurrent&#xD;
      helminth infection (HEL+ and HEL- respectively). In both groups, venipuncture and possibly&#xD;
      apheresis will be performed to understand protective and modulatory T cell and&#xD;
      monocyte/macrophage responses. Subjects will receive treatment for helminth infection and&#xD;
      treatment for LTBI will be offered according to current standard of care guidelines. Two&#xD;
      groups of subjects within the LTBI group will be offered bronchoscopy and lavage --- (a)&#xD;
      those with structural lung damage from prior treated/healed tuberculosis and (b) those with&#xD;
      recent prolonged exposure (greater than or equal to 3 months) to a household contact with&#xD;
      active TB.&#xD;
&#xD;
      The primary objective is to evaluate CD4+ T cell responses and regulatory T cell responses in&#xD;
      HEL+ and HEL- subjects with LTBI at the time of diagnosis (baseline). HEL+ subjects will then&#xD;
      receive treatment for parasitic infection and both groups (HEL+ and HEL-) will be offered&#xD;
      LTBI treatment. Evolution of the baseline TB-specific immune responses on and after LTBI&#xD;
      treatment will then be studied. Additionally, baseline immune responses to mycobacteria will&#xD;
      be contrasted in the HEL+ group with all time points post treatment for helminth infection. A&#xD;
      secondary objective is to evaluate the immune phenotype and functionality of tissue resident&#xD;
      immune cells obtained by bronchoalveolar lavage in subjects with LTBI and structural lung&#xD;
      damage from prior treated/healed pulmonary tuberculosis as well as subjects with recent&#xD;
      prolonged TB exposure from an active TB case irrespective of helminth infection status.&#xD;
&#xD;
      An exploratory objective is to evaluate if there are subsets of subjects within the LTBI&#xD;
      group (irrespective of helminth infection status) who have stable pool of long lasting&#xD;
      antigen-specific IL-2 only producing CD4+ central memory T cells and changes to this pool&#xD;
      after receiving LTBI treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 15, 2014</start_date>
  <completion_date type="Actual">May 11, 2017</completion_date>
  <primary_completion_date type="Actual">May 11, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Define the immunologic differences in CD4+ T cell responses between helminth-infected and uninfected subjects with concomitant latent TB at the time of diagnosis and on serial follow-up.</measure>
    <time_frame>Pre Treatment for LTBI and pre defined post treatment time points</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the immune phenotype and functionality of tissue resident immune cells obtained by bronchoalveolar lavage in subjects with LTBI and either: 1) structural lung damage from prior treated/healed pulmonary tuberculosis or 2) recent prolonge...</measure>
    <time_frame>Pre Treatment for LTBI and pre defined post treatment time points LTBI and pre definedpost treatment timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define the role of stable long lasting antigen-specific IL-2 producing CD4+ central memory T cells in identifying subsets of patients with LTBI</measure>
    <time_frame>Pre Treatment for LTBI and pre defined post treatment time points LTBI and pre defined post treatment timepointspoints</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Latent Tuberculosis Infection</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA&#xD;
&#xD;
        All subjects must meet the following criteria:&#xD;
&#xD;
          -  Subjects must have 1 of the following:&#xD;
&#xD;
               -  Untreated LTBI, defined as positive Quantiferon TB Gold assay; absence of active&#xD;
                  TB disease as determined by history, physical examination, chest X-ray, and&#xD;
                  negative sputum smear and culture for Mtb; and no history of prior treatment for&#xD;
                  LTBI. OR&#xD;
&#xD;
               -  Chronic inactive TB, defined as past history of documented or selfreported active&#xD;
                  pulmonary TB for which treatment was received; current negative sputum smear and&#xD;
                  culture for Mtb; and a positive result on the Quantiferon TB Gold assay. These&#xD;
                  subjects will compose the treatment-induced LTBI group and will not require&#xD;
                  treatment for LTBI.&#xD;
&#xD;
          -  Age 18-70 years. Subjects over the age of 70 will not be included due to the increased&#xD;
             potential for immune senescence&#xD;
&#xD;
          -  With or without clinical/microbiologic/serologic evidence of untreated concurrent&#xD;
             helminth infection&#xD;
&#xD;
          -  Agree to have blood specimens stored for future studies&#xD;
&#xD;
        Subjects undergoing optional bronchoscopy and bronchoalveolar lavage must meet the&#xD;
        following additional inclusion criteria:&#xD;
&#xD;
          -  Subjects must have 1 of the following:&#xD;
&#xD;
               -  Documented or self reported history of prior treated TB with positive Quantiferon&#xD;
                  TB Gold test and structural lung findings of chronic inactive tuberculosis on&#xD;
                  radiologic imaging, defined as: a) calcified Ghon focus with or without apical&#xD;
                  calcified nodules (Simon foci), b) parenchymal or pleural calcification, and/or&#xD;
                  c) apical fibrosis and cavitary changes. OR&#xD;
&#xD;
               -  History of recent prolonged (greater than or equal to 3 months) exposure to a&#xD;
                  confirmed case of active TB disease.&#xD;
&#xD;
          -  Able and willing to arrange to have another person drive them home after the procedure&#xD;
&#xD;
          -  Able and willing not to eat or drink anything for 6 hours prior and 2 hours after the&#xD;
             procedure&#xD;
&#xD;
          -  Agree to have respiratory tract samples stored for future research&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        A subject will be excluded if they meet any of the following criteria:&#xD;
&#xD;
          -  Presence of active TB disease&#xD;
&#xD;
          -  Treatment for helminth infection within the past year&#xD;
&#xD;
          -  Positive at screening for HIV, hepatitis B, and/or hepatitis C Cardiovascular&#xD;
             instability (Blood pressure: Systolic &gt;180 or &lt;90 mm/Hg or Diastolic &gt;100 or &lt; 50&#xD;
             mm/Hg; pulse &lt;40 or &gt;110)&#xD;
&#xD;
          -  Inadequate peripheral venous access&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;11 g/dL)&#xD;
&#xD;
          -  Current use of corticosteroids or other immunosuppressive agents or documented&#xD;
             diagnosis of a primary immunodeficiency disorder&#xD;
&#xD;
          -  Underlying heart disease, lung disease, bleeding disorder, or other conditions that,&#xD;
             in the judgment of the investigator, contraindicates apheresis&#xD;
&#xD;
          -  Temperature greater than or equal to 38.5 degrees C or other clinical evidence of an&#xD;
             acute infection at screening&#xD;
&#xD;
          -  Currently pregnant or breastfeeding&#xD;
&#xD;
        A subject will not be eligible for optional bronchoscopy and bronchoalveolar lavage if they&#xD;
        meet any of the following additional exclusion criteria:&#xD;
&#xD;
          -  History of recent/acute clinically significant pulmonary compromise. This will be&#xD;
             defined by the following criteria:&#xD;
&#xD;
               -  New lung infection or change in status of chronic lung infection or significant&#xD;
                  new findings on chest X-ray or CT scan&#xD;
&#xD;
               -  Asthma that is unstable or required emergent care, urgent care, hospitalization,&#xD;
                  or intubation during the past two years, or that required the use of oral or&#xD;
                  parenteral corticosteroids during the past two years&#xD;
&#xD;
               -  Clinically significant reactive airway disease that does not respond to&#xD;
                  bronchodilators&#xD;
&#xD;
               -  Unstable chronic lung disease such as Chronic Obstructive Pulmonary Disease&#xD;
                  (COPD) or pulmonary fibrosis&#xD;
&#xD;
               -  History of pulmonary hypertension&#xD;
&#xD;
               -  Requirement of supplemental oxygen at rest&#xD;
&#xD;
          -  Unstable angina or uncontrolled heart failure or rhythm disturbance&#xD;
&#xD;
          -  Significant kidney or liver disease&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions), significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws, or use of anticoagulant medications&#xD;
&#xD;
          -  Use of platelet inhibitors including aspirin and NSAIDs within 7 days of procedure or&#xD;
             clopidogrel (Plavix [TM]) within 14 days of procedure or the inability to safely stop&#xD;
             platelet inhibitors for 7-14 days prior to procedures&#xD;
&#xD;
          -  History of allergic reaction to lidocaine, sedative medications like Valium(TM) or&#xD;
             Versed (TM), or narcotic medications like morphine or fentanyl&#xD;
&#xD;
          -  Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             bronchoscopy and bronchoalveolar lavage or impairs a volunteer s ability to give&#xD;
             informed consent for the procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas B Nutman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery County Public Health Services, TB, Refugee and Migrant Health</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Elias D, Akuffo H, Pawlowski A, Haile M, Sch√∂n T, Britton S. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine. 2005 Feb 3;23(11):1326-34.</citation>
    <PMID>15661380</PMID>
  </reference>
  <reference>
    <citation>Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001;19:93-129. Review.</citation>
    <PMID>11244032</PMID>
  </reference>
  <reference>
    <citation>Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006 Oct 1;174(7):831-9. Epub 2006 Jun 23.</citation>
    <PMID>16799072</PMID>
  </reference>
  <verification_date>May 11, 2017</verification_date>
  <study_first_submitted>August 23, 2014</study_first_submitted>
  <study_first_submitted_qc>August 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2014</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunity</keyword>
  <keyword>Co-Infection</keyword>
  <keyword>Parasite</keyword>
  <keyword>Mycobacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

